Financial Performance
5Y price score: (31)
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 137.5%
US$ Per
Share
By default your notes are visible only to you.
72.3
52-week range
96.2
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
2.7 %
Dividend Yield TTM
-
Market cap $
$ 52,323
Price / Earnings TTM
52.2
Price / Book TTM
4.9
PEG TTM
(2.1)
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
12.4 %
(22.3) %
137.5 %
Free cash flow per share growth
147.2 %
122.6 %
239.8 %
Earnings per share growth
(25) %
40.8 %
144 %
Founded: 1,958
Employees: 15,800
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Jul 23, 2026)
1) Strategic Focus and Leadership Changes
- Edwards Lifesciences is committed to a patient-centered innovation strategy, emphasizing sustainable performance and growth in structural heart therapies.
- The company welcomed Doretta Mistras as CFO, highlighting her immediate impact on the team.
- Leadership remains focused on transforming care in structural heart disease through innovation and evidence generation.
2) Financial Performance and Segment Results
- Q2 2026 total sales reached $1.74 billion, a 12.5% YoY increase.
- Adjusted EPS for the quarter was $0.78, with a reaffirmed full-year EPS guidance of $2.95 to $3.05.
- TAVR sales were $1.3 billion, up 10.5% YoY, driven by strong procedural growth and SAPIEN platform differentiation.
- TMTT sales increased 44.8% YoY to $195.9 million, with significant contributions from PASCAL, EVOQUE, and SAPIEN M3.
- Surgical segment sales were $284 million, reflecting a 5% YoY increase.
3) Challenges and Headwinds
- The company anticipates challenges in the second half of 2026 due to high comps from the previous year, which may artificially lower growth rates.
- Foreign exchange impacts are expected to be a headwind, with a projected $35 million impact in the second half.
- Changes in California law affecting R&D tax credits may also influence financial performance.
4) Operational and Product Developments
- Edwards is focused on expanding its TAVR, TMTT, and Surgical portfolios, with several key product launches and approvals expected in the coming months.
- Upcoming milestones include the finalization of the U.S. TAVR NCD and the launch of next-generation PASCAL technology.
- The company aims for TMTT revenue to reach $2 billion by 2030, supported by ongoing product adoption and new indications.
5) Guidance and Outlook
- The full-year sales growth guidance has been increased to 10% to 11%, with TAVR growth guidance raised to 8% to 9%.
- The company expects to maintain its long-term target of 10% average sales growth and operating margin expansion.
- The call did not provide specific details on the PROGRESS trial results or their potential impact on TAVR adoption, which may be critical for future growth.
Bottom line: Edwards Lifesciences is positioned for sustainable growth driven by strong performance across its product segments and strategic leadership. The company’s focus on innovation and evidence generation, coupled with increased guidance for 2026, reinforces confidence in achieving long-term growth targets, despite anticipated short-term headwinds.
Annual Reports, Presentations And IR Contacts
Go to the websiteEdwards Lifesciences — Financial Overview, Stock Price, Market Cap
Edwards Lifesciences is a company. Founded in 1958. As of August 26, 2026, the company's market capitalization is $52322946000 with a current stock price of $90.87.